71 results about "Streptococcus pneumoniae conjugated" patented technology

The invention relates to the use of a composition comprising n Streptococcus pneumoniae polysaccharides conjugated to the tetanus toxoid and p Streptococcus pneumoniae polysaccharides conjugated to the diphtheria toxoid, for manufacturing a vaccine which protects against Clostridium tetani and/or Corynebacterium diphtheriae infections in which: (1) n and p are other than 1, with p being, however, <=15, (2) 2<=n+p<=38, (3) the total amount of conjugated toxoid present in one vaccine dose is sufficient to induce protection against Clostridium tetani and/or Corynebacterium diphtheriae infections.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention belongs to the technical field of biochemistry, and particularly relates to a quinoxaline-N1,N4-dioxide derivative capable of inhibiting the activity of DNA topoisomerase, a preparationmethod and application of the quinoxaline-N1,N4-dioxide derivative. 4,5,-difluoro-2-nitroaniline is used as a raw material for synthesis of the quinoxaline-N1,N4-dioxide derivative, the quinoxaline-N1,N4-dioxide derivative reacts with sodium hypochlorite under catalysis of a basic catalyst, namely sodium hydroxide, and 5,6-difluoro-N-benzofuroxan is obtained; and then the quinoxaline-N1,N4-dioxidederivative reacts with different substrates in Beirut reaction and substitution reaction, and a series of the quinoxaline-N1,N4-dioxide derivative is obtained. According to the quinoxaline-N1,N4-dioxide derivative, the preparation method and application of the quinoxaline-N1,N4-dioxide derivative, quinoxoline-N1,N4-dioxide has good bacteriostatic activity to previously reported gram-negative bacteria, and also had good bacteriostatic activity to actinobacilluspleuropneumoniae and gram-positive bacteria such as staphylococcus aureus and streptococcus pneumoniae.

The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.

The invention discloses a nucleic acid typing detection kit for encephalitis and meningitis. The kit comprises a nucleic acid rapid extraction reagent, a PCR amplification reagent, an encephalitis andmeningitis nucleic acid detection reagent, a positive reference substance and a negative reference substance. The encephalitis and meningitis nucleic acid detection reagent comprises an amplificationprimer and a probe of a streptococcus pneumoniae gene, an amplification primer and a probe of a neisseria meningitidis gene, an amplification primer and a probe of a haemophilus influenzae gene, andan amplification primer and a probe of an internal reference RNP gene. The invention further provides a nucleic acid typing detection method for encephalitis and meningitis. According to the invention, multi-channel primers and probes with encephalitis and meningitis specificity are introduced; the workload can be reduced; the problem that other detection methods are low in specificity and prone to missed diagnosis and misdiagnosis is solved; multiple simultaneous detection of three pathogens in the same system can be achieved, and primers and probes in all channels do not interfere with one another; the sensitivity is good; the specificity is high; accuracy and reliability are achieved; rapidness and convenience are achieved; and whether the three pathogens are infected or not is rapidlydiagnosed.

The invention belongs to the field of chemical pharmaceuticals, and relates to (6R, 7R)-3-hydroxymethyl-7-[alpha-(N, N'-diisopropylamidino thio)-acetamido]-8-oxo-5-thia-1-azabicycle [4, 2, 0]-oct-2-ene-2-carboxylic acid, a preparation method and application thereof. With the adoption of a two-phase process, 7-amino-3-hydroxymethyl-8-oxo-5-thia-1-azabicycle[4.2.0]-oct-2-ene-2-formic acid and bromoacetyl bromide are reacted to obtain an intermediate A; and the intermediate A and N',N-diisopropylthiourea are reacted to obtain the compound provided by the invention. The compound provided by the invention has the antibacterial effects on staphylococcus aureus, streptococcus pneumoniae, enterococcus hirae and enterococcus faecalis etc., especially, the antimicrobial activity on staphylococcus aureus is very strong and is 10 folds stronger than cefathiamidine, the activity on enterococcus faecalis is 15 folds stronger than cefathiamidine, and the activity on streptococcus pneumoniae is strong as well, so that the compound is a potential antibacterial agent.

The invention discloses a preparation method of a strain culture medium containing traditional Chinese medicinal materials. The preparation method comprises the following steps: weighing agar, addinginjection water for dissolving, carrying out moist heat sterilization and cooling for later use; weighing the following raw materials: a carbon source is prepared from 10 to 35 parts of jerusalem artichoke, 10 to 30 parts of lucid ganoderma and 15 to 40 parts of bagasse; a nitrogen source is prepared from 20 to 80 parts of cottonseed meal powder, 15 to 45 parts of peptone, 20 to 50 parts of driedsmall shrimp powder, 15 to 35 parts of corn steep liquor and 10 to 30 parts of bran; inorganic salt and trace elements are as follows: 0.20 to 1.5g/L of MgSO4, 2.5 to 12.5 g/L of NaCl, 0.1 to 2.5 g/Lof K2HPO4, 0.1 to 0.2 g/L of ZnSO4, 0.01 to 0.12 g/L of FeSO4, 0.2 to 1.2 g/L of niacin, 3.5 to 8.5 g/L of adenine, 0.8 to 2.0 g/L of cysteine, 12 to 20g of agar and 1000 parts of water. By adopting the injection water to dissolve the weighed raw materials, determining the volume, adjusting a pH value, carrying out sterilization treatment, and then adding the treated material into a sterilized andcooled agar culture medium, a solid culture medium is prepared. The preparation method of the strain culture medium containing the traditional Chinese medicinal materials, disclosed by the invention,has the advantages that proliferation rate of streptococcus pneumoniae is significantly improved and the possibility of bacterial contamination is reduced.

The invention relates to the technical field of culture dishes and drug sensitivity detection thereof, and particularly provides a culture dish, which comprises a culture dish substrate 1, wherein a plurality of circular rings 2 are arranged on the culture dish substrate 1, the circular rings 2 are not overlapped with one another; a dot 3 is arranged in the center of each circular ring; and a plurality of scale marks 4 are arranged in each circular ring 2. The invention also provides a moxifloxacin drug sensitivity kit, which comprises moxifloxacin drug sensitivity paper and the culture dish,and can be used for sensitivity tests of streptococcus pneumoniae, haemophilus influenzae, hemophilus parainfluenzae, staphylococcus aureus, and the like on the antibacterial drug namely moxifloxacin.